News
Stoke Therapeutics and Biogen have begun dosing in the global Phase III EMPEROR study of zorevunersen for Dravet syndrome, ...
Cambridge, Massachusetts Wednesday, August 13, 2025, 15:00 Hrs [IST] ...
Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...
TipRanks on MSN19h
Stoke Therapeutics Advances RNA Medicine with Strong Q2 Results
Stoke Therapeutics ( ($STOK) ) has released its Q2 earnings. Here is a breakdown of the information Stoke Therapeutics presented to its investors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback